class="wp-theme-Newspaper supp-body td-standard-pack global-block-template-1 tdc-header-template tdc-footer-template td-animation-stack-type0 td-full-layout"
Endocrine disruptor: antiandrogenic. Male reproductive toxicity in animal studies. Developmental concerns in pregnancy. EU has restricted phthalates in toys and childcare products. FDA is reviewing pharmaceutical uses. California Proposition 65 listed. Prefer alternative enteric coating polymers.
Phthalate plasticiser used in enteric coatings for tablets and capsules. Endocrine disruptor — antiandrogenic effects affecting male reproductive development. Metabolite monoethyl phthalate (MEP) detected in urine of most people. Under increasing regulatory restriction globally.
Acts on cellular signalling pathways relevant to the documented clinical indications. Contains bioactive compounds with enzyme-modulating, receptor-binding, or antioxidant properties studied in peer-reviewed literature.
| Population | Safety rating | Max safe dose |
|---|---|---|
| General | Likely unsafe | — |
| Pregnancy | Likely unsafe | — |
| Elderly | Likely unsafe | — |
No peer-reviewed clinical trial data found for this ingredient.
Data by supplement.ge — Public Health Institute of Georgia (PHIG)